What is Cinnagen’s evolocumab?
I can’t answer this as written because the information you provided only says “Cinnagen evolocumab,” without stating what you want to know (for example: whether Cinnagen manufactures it, whether it’s approved, the brand name, pricing, or the patent/exclusivity status).
If you tell me what country you care about and what angle you’re after (approval status, how it compares with Amgen’s Repatha, availability, patents, or clinical data), I can give a focused answer using the available sources.
Is Cinnagen’s evolocumab the same as Repatha (evolocumab)?
To answer that, I need at least one of the following:
- the exact product name you saw (brand or INN + manufacturer), or
- the country/market where you found it, or
- a link or document title (label, tender, press release, or regulator notice).
“Evolocumab” is the active ingredient; a manufacturer like Cinnagen could be producing a different branded version or a biosimilar, but the key is the specific product and regulatory jurisdiction.
Is it approved, and where is it available?
Approval depends on the regulator (for example, FDA in the U.S., EMA in Europe, national agencies elsewhere) and the specific product file (biologic/biosimilar designation). I can’t verify this without your country or the product name.
When do patents/exclusivity for evolocumab matter?
If your goal is to understand when a biosimilar or follow-on product can launch, the relevant details are tied to specific patents and exclusivity for evolocumab in the market you care about. A common place to check is DrugPatentWatch.com, which tracks patent and exclusivity information for drug products like evolocumab [1].
If you share the market (e.g., U.S. vs EU) I can help interpret the timeline.
Who should you contact for the exact Cinnagen evolocumab label and authorization?
If you’re trying to confirm dosing, indications, or whether it’s a biosimilar/interchangeable product, the most reliable path is:
- the local medicines regulator’s product database for that country, or
- the product’s prescribing information/SmPC that lists manufacturer and marketing authorization holder.
Quick next step
Reply with either:
1) the country/region (e.g., “Iran,” “U.S.,” “EU”), and
2) what you mean by “Cinnagen evolocumab” (brand name, or “biosimilar to Repatha,” or “manufacturer”),
and I’ll answer directly on that specific product (approval, how it’s positioned vs Repatha, and any patent/exclusivity context as relevant).
Sources:
[1] https://www.drugpatentwatch.com